Regentys and Cook Partnering on Ongoing Development of Ulcerative Colitis Therapy

Regentys and Cook Partnering on Ongoing Development of Ulcerative Colitis Therapy
Regentys and Cook Biotech are teaming up to continue developing a treatment for the inflammatory bowel disease ulcerative colitis. Under the agreement, Cook will direct the development of Regentys’ ECMH Rectal Solution, or extracellular matrix hydrogel, which Regentys plans to start clinical trials on in 2018. Cook will also manufacture the therapy. “We have been working with the outstanding team at Cook Biotech for the last several months to complete the technology transfer of our product in order to scale our manufacturing for our clinical program, which will begin in the second half of 2018,” Brian Andersen, Regentys's chief business officer, said in a press release. ECMH is a non-drug, non-surgical treatment for ulcerative colitis. It is based on extracellular matrix, or ECM, the non-cell component in all tissue and organs that provides the physical structure for the cell constituents. It is fundamental for the normal functioning and stability of tissue development. “This is a unique application of ECM that will help treat a very debilitating disease,” said Umesh Patel, the president of Cook Biotech. “We’re looking forward to working with the team at Regentys to bring this product to market.” Hallmarks of ulcerative colitis include chronic diarrhea, pain, bleeding, urgency to defecate and increased risk of cancer. The disease causes inflammation and sores
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *